Genome-wide association study of antipsychotic induced QTc interval prolongation.
The Pharmacogenomics Journal 12 (2): 165-172.
The influence of five monoamine genes on trajectories of depressive symptoms across adolescence and young adulthood.
Development and Psychopathology 24 (1): 267-285.
Pharmacogenomic study of side effects for antidepressant treatment options in STAR*D.
Psychological Medicine 42 (6): 1151-1162.
SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE Study.
Schizophrenia Research 135 (1-3): 200-201.
The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.
European Journal of Pharmacology 679 (1-3): 75-80.
The Center for Biomarker Research and Personalized Medicine at Virginia Commonwealth University: advancing psychiatric drug treatment.
Personalized Medicine 9 (5): 479-483.
Genomewide pharmacogenomic study of citalopram-induced side effects in STAR*D.
Translational Psychiatry 2: e129.
MBD-seq as a cost-effective approach for methylome-wide association studies: demonstration in 1500 case-control samples.
Epigenomics 4 (6): 605-621.